2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 339

Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 67

Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 259

Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 255

Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 237

Determination of Muscle Pressure in Patients with Fibromyalgia by Two Examiners; The Examiners Get Similar Results

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 747

Detrimental Factors Affecting the First-year Clinical Response in Korean Patients with Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 267

Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 168

Development and Usability Testing of Take Charge: An Email Series to Increase Knowledge of Self-Management Skills in People with Lupus

Education/Community Programs Poster – ARP

9:00AM-11:00AM: Abstract Number: 341

Development of a Multivariable Improvement Measure for Gout

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 562

Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 601

Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 798

Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 145

Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 718

Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 723

Diagnosis of Systemic Sclerosis: How and When

Systemic Sclerosis & Related Disorders – Clinical Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].